Description |
Product Type |
Product Size |
Injection |
1'S |
Product Company |
Roche Pharma |
Atezolizumab 1200mg/20ml |
Product Type |
Product Size |
Product Company |
Injection |
1'S |
Roche Pharma |
|
Product Type |
Product Size |
Injection |
1'S |
Product Company |
Martin Dow |
Ondansetron 8mg/4ml |
Product Type |
Product Size |
Injection |
1'S |
Product Company |
Roche Pharma |
Trastuzumab 600mg/5ml |
Product Type |
Product Size |
Tablets |
30'S |
Product Company |
Beacon Pharmaceuticals |
Sorafenib 200mg |
Product Type |
Product Size |
Product Company |
Injection |
1'S |
Pharmedic |
|
Content | "
Atezolizumab, sold under the brand name Tecentriq, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer, triple-negative breast cancer, small cell lung cancer, hepatocellular carcinoma, and alveolar soft part sarcoma. | "
Rituximab is a biological therapy used for rheumatoid arthritis, lupus, vasculitis and dermatomyositis | Ondansetron is used to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery. Ondansetron is in a class of medications called serotonin 5-HT3 receptor antagonists. It works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting. | Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor positive. It may be used by itself or together with other chemotherapy medication. | Sorafenib is used to treat late-stage kidney cancer (advanced renal cell carcinoma), liver cancer (hepatocellular carcinoma) that cannot be treated by surgery, and differentiated thyroid cancer that has come back or spread to other parts of your body. Sorafenib is an antineoplastic (cancer) agent.
| Cyclophosphamide is a medication primarily used in the management and treatment of neoplasms, including multiple myeloma, sarcoma, and breast cancer. |
Reviews
There are no reviews yet.